Veera Nurmela, Anni Juntunen, Tuomas Selander, Sanna Pasonen-Seppänen, Outi Kuittinen, Satu Tiainen, Aino Rönkä
{"title":"由于免疫检查点抑制剂相关不良事件住院的转移性癌症患者生存率低。","authors":"Veera Nurmela, Anni Juntunen, Tuomas Selander, Sanna Pasonen-Seppänen, Outi Kuittinen, Satu Tiainen, Aino Rönkä","doi":"10.1080/1750743X.2025.2492541","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting approximately half of ICI-treated patients. irAEs may be severe and result in hospitalization. This study examined the risk factors and outcomes of irAE-related hospitalization.</p><p><strong>Methods: </strong>We conducted a retrospective study including 202 metastatic cancer patients treated with ICIs at Kuopio University Hospital, Finland, in 2015-2022.</p><p><strong>Results: </strong>IrAEs occurred in 57.4% of the patients. About 26.0% of them required inpatient treatment. Hospitalization was associated with severe (grades III - IV) toxicities and need for systemic corticosteroids. Median overall survival (mOS) for hospitalized patients was 12.9 months and for outpatients with irAEs 26.9 months (<i>p</i> = 0.006). The duration of ICI therapy was 1.8 months in hospitalized patients and 5.0 months in outpatients (<i>p</i> < 0.001). The median maximum glucocorticoid doses were 52 mg and 100 mg, respectively (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>IrAE-related hospitalization deteriorated the survival of ICI-treated patients, likely due to decreased biological efficacy of ICIs resulting from short therapy periods and strong immunosuppression by glucocorticoids.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"17 5","pages":"339-346"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045564/pdf/","citationCount":"0","resultStr":"{\"title\":\"Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events.\",\"authors\":\"Veera Nurmela, Anni Juntunen, Tuomas Selander, Sanna Pasonen-Seppänen, Outi Kuittinen, Satu Tiainen, Aino Rönkä\",\"doi\":\"10.1080/1750743X.2025.2492541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting approximately half of ICI-treated patients. irAEs may be severe and result in hospitalization. This study examined the risk factors and outcomes of irAE-related hospitalization.</p><p><strong>Methods: </strong>We conducted a retrospective study including 202 metastatic cancer patients treated with ICIs at Kuopio University Hospital, Finland, in 2015-2022.</p><p><strong>Results: </strong>IrAEs occurred in 57.4% of the patients. About 26.0% of them required inpatient treatment. Hospitalization was associated with severe (grades III - IV) toxicities and need for systemic corticosteroids. Median overall survival (mOS) for hospitalized patients was 12.9 months and for outpatients with irAEs 26.9 months (<i>p</i> = 0.006). The duration of ICI therapy was 1.8 months in hospitalized patients and 5.0 months in outpatients (<i>p</i> < 0.001). The median maximum glucocorticoid doses were 52 mg and 100 mg, respectively (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>IrAE-related hospitalization deteriorated the survival of ICI-treated patients, likely due to decreased biological efficacy of ICIs resulting from short therapy periods and strong immunosuppression by glucocorticoids.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\"17 5\",\"pages\":\"339-346\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045564/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2025.2492541\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2492541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events.
Aims: Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting approximately half of ICI-treated patients. irAEs may be severe and result in hospitalization. This study examined the risk factors and outcomes of irAE-related hospitalization.
Methods: We conducted a retrospective study including 202 metastatic cancer patients treated with ICIs at Kuopio University Hospital, Finland, in 2015-2022.
Results: IrAEs occurred in 57.4% of the patients. About 26.0% of them required inpatient treatment. Hospitalization was associated with severe (grades III - IV) toxicities and need for systemic corticosteroids. Median overall survival (mOS) for hospitalized patients was 12.9 months and for outpatients with irAEs 26.9 months (p = 0.006). The duration of ICI therapy was 1.8 months in hospitalized patients and 5.0 months in outpatients (p < 0.001). The median maximum glucocorticoid doses were 52 mg and 100 mg, respectively (p < 0.001).
Conclusions: IrAE-related hospitalization deteriorated the survival of ICI-treated patients, likely due to decreased biological efficacy of ICIs resulting from short therapy periods and strong immunosuppression by glucocorticoids.
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
